Evidence map›Paper›PMID 37448451›Full record

ReviewFrontiers in synaptic neuroscience2023

Rethinking the network determinants of motor disability in Parkinson's disease.

Dalton James Surmeier, Shenyu Zhai, Qiaoling Cui, DeNard V Simmons

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in synaptic neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progression.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Dalton James SurmeierDepartment of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Shenyu ZhaiDepartment of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Qiaoling CuiDepartment of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
DeNard V SimmonsDepartment of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Northwestern University · US

Funding

DOPAMINERGIC AND MUSCARINIC SIGNALING IN THE STRIATUMR37NS034696 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI DALTON JAMES SURMEIER · 2001 to 2026
$7.3M
Determinants of Basal Ganglia Pathology in Parkinson's DiseaseR01NS121174 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BEVAN, MARK D, SURMEIER, DALTON JAMES · 2021 to 2025
$3.6M
NINDS NIH HHS R01 NS121174NINDS NIH HHS R37 NS034696
6 · The paper itself

Abstract

For roughly the last 30 years, the notion that striatal dopamine (DA) depletion was the critical determinant of network pathophysiology underlying the motor symptoms of Parkinson's disease (PD) has dominated the field. While the basal ganglia circuit model underpinning this hypothesis has been of great heuristic value, the hypothesis itself has never been directly tested. Moreover, studies in the last couple of decades have made it clear that the network model underlying this hypothesis fails to incorporate key features of the basal ganglia, including the fact that DA acts throughout the basal ganglia, not just in the striatum. Underscoring this point, recent work using a progressive mouse model of PD has shown that striatal DA depletion alone is not sufficient to induce parkinsonism and that restoration of extra-striatal DA signaling attenuates parkinsonian motor deficits once they appear. Given the broad array of discoveries in the field, it is time for a new model of the network determinants of motor disability in PD.

Indexed as

basal gangliacircuitdopamineneuromodulationParkinson’s diseaseplasticity

Identifiers

PMID37448451
PMCPMC10336242
OpenAlexW4382399915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.